Savara(US:SVRA) Globenewswire·2025-10-13 20:00Core Viewpoint - The Gross Law Firm is notifying shareholders of Savara Inc. regarding a class action lawsuit related to misleading statements and omissions concerning the company's drug application for MOLBREEVI, which may have impacted stock value [1][3]. Group 1: Allegations - The complaint alleges that during the class period from March 4, 2024, to May 23, 2025, Savara Inc. made materially false and misleading statements regarding the MOLBREEVI BLA, particularly about its chemistry, manufacturing, and controls [3]. - It is claimed that the FDA was unlikely to approve the MOLBREEVI BLA in its current form, which would delay Savara's submission timeline and increase the need for additional capital [3]. Group 2: Class Action Details - Shareholders who purchased shares of SVRA during the specified class period are encouraged to register for the class action, with a deadline of November 7, 2025, to seek lead plaintiff status [4]. - Participants will be enrolled in a portfolio monitoring software to receive updates on the case's progress, with no cost or obligation to participate [4]. Group 3: Law Firm's Mission - The Gross Law Firm aims to protect investors' rights against deceit, fraud, and illegal business practices, emphasizing the importance of responsible corporate behavior [5].